Literature DB >> 15364919

Protein kinase C Theta inhibits insulin signaling by phosphorylating IRS1 at Ser(1101).

Yu Li1, Timothy J Soos, Xinghai Li, Jiong Wu, Matthew Degennaro, Xiaojian Sun, Dan R Littman, Morris J Birnbaum, Roberto D Polakiewicz.   

Abstract

Obesity and stress inhibit insulin action by activating protein kinases that enhance serine phosphorylation of IRS1 and have been thus associated to insulin resistance and the development of type II diabetes. The protein kinase C (PKC) is activated by free-fatty acids, and its activity is higher in muscle from obese diabetic patients. However, a molecular link between PKC and insulin resistance has not been defined yet. Here we show that PKC phosphorylates IRS1 at serine 1101 blocking IRS1 tyrosine phosphorylation and downstream activation of the Akt pathway. Mutation of Ser(1101) to alanine makes IRS1 insensitive to the effect of PKC and restores insulin signaling in culture cells. These results provide a novel mechanism linking the activation of PKC to the inhibition of insulin signaling.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15364919     DOI: 10.1074/jbc.C400186200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  118 in total

Review 1.  Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction.

Authors:  Katsutaro Morino; Kitt Falk Petersen; Gerald I Shulman
Journal:  Diabetes       Date:  2006-12       Impact factor: 9.461

Review 2.  NOD1: An Interface Between Innate Immunity and Insulin Resistance.

Authors:  Sydney L Rivers; Amira Klip; Adria Giacca
Journal:  Endocrinology       Date:  2019-05-01       Impact factor: 4.736

3.  Insulin and metabolic stress stimulate multisite serine/threonine phosphorylation of insulin receptor substrate 1 and inhibit tyrosine phosphorylation.

Authors:  Nancy J Hançer; Wei Qiu; Christine Cherella; Yedan Li; Kyle D Copps; Morris F White
Journal:  J Biol Chem       Date:  2014-03-20       Impact factor: 5.157

4.  Emerging Pharmacological Targets for the Treatment of Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Type 2 Diabetes.

Authors:  Leigh Goedeke; Rachel J Perry; Gerald I Shulman
Journal:  Annu Rev Pharmacol Toxicol       Date:  2019-01-06       Impact factor: 13.820

5.  PKCθ activation in pancreatic acinar cells by gastrointestinal hormones/neurotransmitters and growth factors is needed for stimulation of numerous important cellular signaling cascades.

Authors:  Veronica Sancho; Marc J Berna; Michelle Thill; R T Jensen
Journal:  Biochim Biophys Acta       Date:  2011-07-23

6.  Burn injury-induced IRS-1 degradation in mouse skeletal muscle.

Authors:  X-M Lu; Rg Tompkins; Aj Fischman
Journal:  Int J Burns Trauma       Date:  2013-01-24

7.  Constitutively active Akt inhibits trafficking of amyloid precursor protein and amyloid precursor protein metabolites through feedback inhibition of phosphoinositide 3-kinase.

Authors:  Diana W Shineman; Aleksandra S Dain; Minkyu L Kim; Virginia M-Y Lee
Journal:  Biochemistry       Date:  2009-05-05       Impact factor: 3.162

8.  Exposure to ambient particulate matter induces a NASH-like phenotype and impairs hepatic glucose metabolism in an animal model.

Authors:  Ze Zheng; Xiaohua Xu; Xuebao Zhang; Aixia Wang; Chunbin Zhang; Maik Hüttemann; Lawrence I Grossman; Lung Chi Chen; Sanjay Rajagopalan; Qinghua Sun; Kezhong Zhang
Journal:  J Hepatol       Date:  2012-08-15       Impact factor: 25.083

9.  S6K directly phosphorylates IRS-1 on Ser-270 to promote insulin resistance in response to TNF-(alpha) signaling through IKK2.

Authors:  Jin Zhang; Zhanguo Gao; Jun Yin; Michael J Quon; Jianping Ye
Journal:  J Biol Chem       Date:  2008-10-24       Impact factor: 5.157

10.  Overproduction of phosphoprotein enriched in diabetes (PED) induces mesangial expansion and upregulates protein kinase C-beta activity and TGF-beta1 expression.

Authors:  F Oriente; S Iovino; A Cassese; C Romano; C Miele; G Troncone; M Balletta; A Perfetti; G Santulli; G Iaccarino; R Valentino; F Beguinot; P Formisano
Journal:  Diabetologia       Date:  2009-09-30       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.